ISRCTN22165762已完成不适用
A double blind, randomised, placebo-controlled trial investigating the use of levobupivicaine transversus abdominis blocks for colorectal laparoscopic surgery
Worthing and Southlands Hospitals NHS Trust (UK)0 个研究点目标入组 100 人开始时间: 2008年11月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Men and women, over the age of 18 years
- •2. Receiving any type of elective, laparoscopic colorectal surgery for benign or malignant disease
- •3. Operations conducted at Worthing Hospital, West Sussex, by any of the colorectal surgeons
排除标准
- •1. Patients under the age of 18 years
- •2. Undergoing open or emergency surgery
- •3. A history of renal failure, coagulopathies or allergy to levobupivicaine
- •4. Reoperations for complications
- •5. Previous abdominal surgery
- •6. Not undergoing colorectal surgery
- •7. Patients in which an intentional stoma is to be fashioned
- •8. Refusal to participate
研究者
相似试验
进行中（未招募）
1 期
A study to find out how nintedanib is taken up in the body and how well it is tolerated in children and adolescents with Interstitial Lung Disease (ILD).MedDRA version: 21.1Level: PTClassification code 10022611Term: Interstitial lung diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersInterstitial Lung DiseaseEUCTR2018-004530-14-GR30
进行中（未招募）
1 期
A trial to compare nintedanib with placebo for patients with scleroderma related lung fibrosisPatients with Systemic Sclerosis and associated Interstitial Lung DiseaseMedDRA version: 19.1Level: LLTClassification code 10012977Term: Diffuse systemic sclerosisSystem Organ Class: 100000004859MedDRA version: 19.1Level: LLTClassification code 10036814Term: Progressive systemic sclerosisSystem Organ Class: 100000004859MedDRA version: 19.1Level: PTClassification code 10042954Term: Systemic sclerosis pulmonarySystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 19.1Level: LLTClassification code 10025109Term: Lung involvement in systemic sclerosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 19.1Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859EUCTR2015-000392-28-NOBoehringer Ingelheim Norway KS819
进行中（未招募）
1 期
A trial to compare nintedanib with placebo for patients with scleroderma related lung fibrosisEUCTR2015-000392-28-DKBoehringer-Ingelheim Pharma GmbH & Co. KG750
进行中（未招募）
1 期
A study to find out how nintedanib is taken up in the body and how well it is tolerated in children and adolescents with Interstitial Lung Disease (ILD).Interstitial Lung DiseaseEUCTR2018-004530-14-GBBoehringer Ingelheim Limited30
进行中（未招募）
1 期
A trial to compare nintedanib with placebo for patients with scleroderma related lung fibrosisPatients with Systemic Sclerosis and associated Interstitial Lung DiseaseMedDRA version: 18.0Level: LLTClassification code 10012977Term: Diffuse systemic sclerosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: LLTClassification code 10036814Term: Progressive systemic sclerosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10042954Term: Systemic sclerosis pulmonarySystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 18.0Level: LLTClassification code 10025109Term: Lung involvement in systemic sclerosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 18.0Level: PTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-000392-28-ESBoehringer Ingelheim España, S.A.750